Embed Size (px)
Citation preview
September 9 - 10, 2019 | Boston
THE FUTURE OF PHARMACEUTICAL DEVELOPMENT
POST EVENT REPORT
9th American
learned something new
and useful
97.8%
would recommend to
a colleague
97%
said the Summit had greatly exceeded,
exceeded, or met their expectations
90%
would attend again
89.4%
Statistics
registered attendees
Over
250
companiesand organisationsrepresented
150+
Highlights video2016 2017 2018 2019
Summit growth:
166
atte
ndee
s
181
atte
ndee
s
205
atte
ndee
s
253
atte
ndee
s
2
“Good experience and exposure to current ongoing developmental and
technical improvements”Faisal Khan, Senior Research Associate, Takeda
Pharmaceuticals Company
“It is a good opportunity to learn all the updated technologies for Drug
Delivery and Formulation.”Wenjiao Song, Senior Scientist, Pfizer Inc.
“Excellent program”Peixuan Guo, Endowed Chair
Professor, The Ohio State University
“It was very informative, the talks were interesting.”
Eric Ehrnsperger, Principal Scientist, Ferring Pharmaceuticals
“High quality presentations”Dan Groszmann, Senior Manager, Amgen
Testimonials
“Great summit”Yan He, Principal Scientist, Sanofi
“Great event, great presentations, met new people”
Miranda Perry, Senior Scientist, AbbVie
“Well organized conference with great talks.”
Istvan Enyedy, Principal Scientist, Biogen
3
PresentationsClick on the buttons below to view the presentation slides.
Unlocking Full Formulation Performance through Advanced ExcipientsDrug Delivery & Formulation SummitBoston, Massachusetts
Kathryn Hewlett, PhDSeptember 9th, 2019
Current Trends in Technology and Regulatory Landscapes for Developing and Bringing Generics and Innovative Medicines to MarketRosario LoBrutto, Head of Scientific Affairs, Sandoz
Ultrasmall Targeted Nanoparticles with Engineered Antibody Fragments for Imaging of HER2-overexpressing Breast CancerMarcello Marelli, Senior Scientist Antibody Discovery and Protein Engineering, AstraZeneca
Unlocking Full Formulation Performance through Advanced ExcipientsDr. Kathryn Hewlett, Application Development & Innovation Scientist, DuPont Nutrition & Biosciences
Ultrasmall Targeted Nanoparticles with Engineered Antibody Fragments for Imaging of HER2-overexpressing Breast Cancer
Marcello MarelliAntibody Discovery and Protein Engineering (ADPE)
Company Restricted17 May 2019
Current Trends in Technology and Regulatory Landscapes for Developing and Bringing
Complex Generics and Innovative Medicines to Market
Sandoz, Inc (A Novartis Division)
Rosario LoBrutto, Ph.D.Head of Scientific AffairsSandoz Pharmaceuticals
Presentation: DDF, Sept.9, 2019 (Boston, USA)
Intracutaneous Microneedle Patch Delivery System for the Treatment of Acute Migraine
September 9, 2019
Yi Ao
©2019 Zosano Pharma Corp.
Hard-to-Stabilize Proteins and Peptides: Can Recombinant Human Albumin be an Effective Approach?Eleonora Cerasoli, Ph.D., Science Manager, Technology Group, Albumedix
Incorporating Behaviour Design into Digital Health ToolsPaul Upham, Head, Smart Devices, Genentech
Intracutaneous Microneedle Patch Delivery System for the Treatment of Acute MigraineYi Ao, Associate Director, Zosano Pharma
Incorporating Behavior Design into Digital Health ToolsPaul UphamHead, Smart DevicesRoche / Genentech
9 September 2019Eleonora Cerasoli American DDF Summit - 2019 Boston
Recombinant human albumin. An effective approach for hard-to-stabilise biologics
ORAL THIN FILMS -WHY THE MUCOFILM® AND THE RAPIDFILM® ARE EXACTLY WHAT YOU NEED
Dr. Ahmad Ghoniem – tesa Labtec – your global CDMO for patches and films – by your side from iea to market
Formulation Development Gap Assessment for An In-licensed Program: A Case StudyNazila Miller, Director, Drug Product Development, Takeda
Modelling Autoinjector Injection Time DistributionJean-René Authelin, Global Head of Pharmaceutical Engineering, Sanofi
Transmucosal Delivery – Using the Mucofilm® Technology to Bypass the First Pass EffectDr. Ahmad Ghoniem, Pharmacist - Business Development Manager, tesa Labtec North America
Modeling of Autoinjectors
JR Authelin SANOFI R&D, Pharmaceutical Sciences Operations In name of the team : Thomas Van der Burg, Maximilian Michel, Michel Becker, Iwo Iwnicki, Lionel Bardet, Nima Ajaghari DDF Boston September 10th 2019
DDF Boston Mathematical Modelling of Autoinjectors 1
Formulation Development Gap Assessment for An In-licensed Program: A Case Study 10 Sept 2019, DDF Summit, Boston, MA
Drug Product Development, Shire HGT Inc., Lexington, MA, A Takeda Company Nazila Miller, Ph.D., Director
Confidential - for internal use only
4
PresentationsClick on the buttons below to view the presentation slides.
Understanding Developability Assessment of Small MoleculesSudhakar Garad, Global Head of Chemical and Pharmaceutical Profiling, Novartis Institutes for BioMedical Research
Solubility Strategies at the Interface of Drug Discovery and DevelopmentPhilippe Lienard, CMC Pre-Development Science Leader, SanofiSolubility Strategies at the Interface
of Drug Discovery and Development Dr. Philippe LIENARD
Pho
to c
redi
ts: ©
Drug Delivery and Formulation Conference, Boston
Understanding Developability Assessment of Small Molecules
Sudhakar Garad, Ph.D.Novartis Cambridge, [email protected] 9th 2019
Applying ICH Q12 to Combination ProductsDiane Harper, Director Regulatory Affairs-CMC, Merck
Machine Learning Models for Predicting P-gp and BCRP Mediated EffluxIstvan Enyedy, Principal Scientist, Biogen
1Biogen | Confidential and Proprietary
September 9, 2019
Istvan J. Enyedy
Machine Learning Models for Predicting P-gp and BCRP Mediated Efflux
APPLYING ICH Q12 TO COMBINATION PRODUCTS
Diane Harper, PhD, JD, RACDirector, Regulatory-CMC Combination ProductsMerck & Co., Inc.
2019 American Drug Delivery & Formulations SummitBoston, MA; September 2019
Harnessing the Power of the Digital Exhaust to Improve Patient OutcomesGraham Jones, Director of Innovation, Novartis
RNA Nanotechnology for Drug Delivery and FormulationPeixuan Guo, Sylvan G. Frank Endowed Chair in Pharmaceutics and Drug Delivery Systems, The Ohio State University
RNA Nanotechnology for Drug Delivery and Formulation
Peixuan Guo
Endowed Chair, College of Pharmacy and College of Medicine, Director, Center for RNA Nanobiotech and Nanomedicine,
The Ohio State University, Columbus, OH USA
President, International Society of RNA Nanotechnology and Nanomedicine (ISRNN)
Harnessing the Power of the Digital Exhaust to Improve Patient Outcomes
DDF – September 9, 2019Graham B. Jones
Director of Innovation, Novartis AGProfessor of Medicine, Tufts Medical Center
Thinklabs
5
Who was there? The summit attracts senior pharmaceutical development and formulation scientists from across industry and academia. Organisations in attendance in 2019 included:
6
10th Global
Who was there?
10th Global
7
Who was there?
10th Global
77.4% 18.2% 4.4%Pharmaceuticals Delivery / Formulation
ServicesUniversities
Oral
Stability
Injection
Solubility
Pre-formulation
Polymers
Bioavailability
Excipients for solid dosage forms formulations
Extended release
Nanotechnology
Excipients for injectables
formulations
Sustained release
Spray drying
Nano
Lipids
53.4%
53.4%
48.3%
48.3%
48.3%
46.6%
44.8%
43.1%
41.4%
37.9%
37.9%
36.2%
34.5%
32.8%
32.8%
8
By seniority: Scientist/specialist 54.1% Director 27.3% VP 6.6% C-level 4.9% Manager 3.8% Head 3.3%
By company type:
Common job functions:
• R&D • Analytical Development • Pharmaceutical Development • Formulation Development • Technical Development • Device Development • Process Development • Drug Development • CMC • Human Factors • Innovation • Business Development
Priority investment areas
Commercial Partners Thank you to our Commercial Partners, without their support the summit couldn’t exist.
Foster Delivery Sciencewww.deliveryscience.com
Enable Injectionswww.enableinjections.com
DuPont Nutrition & Healthwww.dupont.com
Captisolwww.captisol.com
Biopharma Groupwww.biopharma.co.uk
Albumedixwww.albumedix.com
Emergent BioSolutionswww.ebsi.com/CMO
Datwylerwww.datwyler.com
Cambridge Design Partnershipwww.cambridge-design.com
Arcinovaarcinova.com
Agilentwww.agilent.com
DPT Laboratorieswww.dptlabs.com
Intertekwww.intertek.com
LTS Lohmannwww.ltslohmann.de
Microporemicroporetech.com
Leon-Nanodrugswww.leon-nanodrugs.com
Lonza Pharma and Biotechwww.lonza.com
MedPharmwww.medpharm.com
Halo Labswww.halolabs.com
Gore & Associateswww.gore.com/pharmbio
9
Commercial Partners Thank you to our Commercial Partners, without their support the summit couldn’t exist.
Pace Life Scienceswww.pacelifesciences.com
Precision Nanosystemswww.precisionnano systems.com
Munitwww.munit.com
PMC Isochemwww.pmcisochem.fr
Quotient Scienceswww.quotientsciences.com
Upperton Pharma Solutionsupperton.com
Sorrel Medicalwww.sorrelmedical.com
Sensile Medicalwww.sensile-medical.com
Tesa Labtecwww.tesa-labtec.com
Soncebozwww.medical.sonceboz.com
Redshift Bioanalyticsredshiftbio.com
Commecial Partner Testimonials
10
BOOK YOUR PLACE EARLY
As a delegate
We return to San Diego in 2020 with more exclusive case studies from leading pharma experts. You can expect an agenda featuring the world’s leading brands. The speakers will once again be senior executives with a wealth of experience to share with you. Subjects covered will include:
• Formulation design for poorly soluble compounds• The potential of nanotechnology for better deliverability• The latest controlled released technologies• Improving patient compliance by harnessing data and the latest smart device technology• Optimising formulations for continuous manufacturing• Overcoming the blood brain barrier and challenges in oral delivery of biologics• Reformulation and biosimilar As a commercial partner
If you sell solutions or services in the drug development or delivery space, then get in touch asap. Prime spaces on the agenda and in the exhibition hall always sell out early.
Follow us:#DDFSummit
Looking ahead to 2020
To find out more about commercial partner opportunities contact
Alexandra Krcho on [email protected]
or call her on +44 (0) 203 874 9205
10th American
September 14 – 15, 2020 | San Diego
11
